Thoughtworks Analysts Cut Their Forecasts After Weak Q2 Results

Thoughtworks Holding, Inc. (NASDAQ: TWKS) reported worse-than-expected second-quarter financial results and issued third-quarter guidance below estimates.

Thoughtworks Holding, Inc. (NASDAQ:TWKS) reported worse-than-expected second-quarter financial results and issued third-quarter guidance below estimates.

Thoughtworks posted adjusted earnings of 3 cents per share, missing market estimates of 4 cents per share. The company’s sales came in at $287.21 million, versus expectations of $301.50 million.

Thoughtworks said it sees third-quarter revenue of $275 million to $285 million, versus estimates of $326.93 million. The company expects adjusted earnings of 2 cents to 3 cents per share, versus expectations of 12 cents per share.

Thoughtworks shares dipped 25.8% to close at $5.21 on Tuesday and lost 0.2% in today’s pre-market trading session.

These analysts made changes to their price targets on Thoughtworks following earnings announcement.

  • RBC Capital cut the price target on Thoughtworks from $10 to $6. RBC Capital analyst Daniel Perlin downgraded the stock from Outperform to Sector Perform.
  • Citigroup slashed the price target on Thoughtworks from $7 to $5. Citigroup analyst Ashwin Shirvaikar maintained a Neutral rating.
  • Piper Sandler analyst Arvind Ramnani, on Tuesday, lowered the price target on the stock from $7 to $6.

 

Now Read This: Lyft, Disney And 3 Stocks To Watch Heading Into Wednesday

Total
0
Shares
Related Posts
Read More

Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility

Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that funds managed by Oaktree Capital Management, L.P. ("Oaktree") have extended to Mesoblast the availability of up to an additional US$30.0 million of its US$90 million five year facility subject to achieving certain milestones on or before September 30, 2023.

MESO